• Medical Professionals
    • Information for Healthcare Providers
    • Clinical Studies
    • Expanded Access
    • Educational Grants
    • Request Information
  • Press Releases
  • Suppliers
  • Skip to main content
  • Skip to footer

Atara Biotherapeutics

  • Our Company
    • About Us
    • Responsibility
  • Technology
  • Pipeline
    • Atara Pipeline
    • Tab-cel®
    • ATA188
    • ATA3219
    • ATA2271/ATA3271
  • Patients & Families
    • Our Mission
    • Stories of Strength
    • About EBV
    • PTLD
    • Multiple Sclerosis
    • Clinical Studies
    • Expanded Access
  • Investors & Media
    • Investors & Media
    • News & Events
    • Financial Results
    • ATRA Stock
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Careers
    • Careers Home
    • Career Areas
    • Job Search
  • Contact
  • Medical Professionals
  • Press Releases
  • Suppliers
  • LinkedIn
  • Twitter
Investors & Media

Investors & Media

  • Investors & Media
  • News & Events
    • Overview
    • Press Releases
    • Events
    • Presentations
    • Email Alerts
    • Investor & Media Contacts
  • Financial Results
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • ATRA Stock
    • Quote
    • Charts
    • Historical Data
    • FAQ
    • Classification Info
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Contact The Board
  • News
  • Careers

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • Events
  • Presentations
  • Email Alerts
  • Investor & Media Contacts

Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference

Nov 23, 2022 8:00am EST

Atara Biotherapeutics to Participate at the Stifel Healthcare Conference

Nov 09, 2022 4:01pm EST

Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress

Nov 08, 2022 4:01pm EST

Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 04, 2022 4:01pm EDT

Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

Nov 01, 2022 4:05pm EDT

Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022

Oct 26, 2022 2:01am EDT

CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

Oct 14, 2022 7:08am EDT

Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 10, 2022 4:01pm EDT

Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre

Sep 28, 2022 4:01pm EDT

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma Conference

Aug 31, 2022 4:01pm EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...31
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed

    Footer

    • LinkedIn
    • Twitter
    © 2023 Atara Biotherapeutics, Inc. All rights reserved.
    • Privacy Policy
    • Terms of Use
    • Sitemap